Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial-Reference-Cited by-同舟云学术

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

Published:2018-08-31 Issue:4 Volume:68 Page:535-544
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Orkin Chloe¹²,Squires Kathleen E³,Molina Jean-Michel⁴,Sax Paul E⁵,Wong Wing-Wai⁶,Sussmann Otto⁷,Kaplan Richard⁸,Lupinacci Lisa⁹,Rodgers Anthony⁹,Xu Xia⁹,Lin Gina⁹,Kumar Sushma⁹,Sklar Peter⁹,Nguyen Bach-Yen⁹,Hanna George J⁹,Hwang Carey⁹,Martin Elizabeth A⁹,

Affiliation:

1. Queen Mary University

2. Royal London Hospital, United Kingdom

3. Thomas Jefferson University, Philadelphia, Pennsylvania

4. University of Paris Diderot, Hôpital Saint-Louis, Assitance Publique Hôpitaux de Paris, France

5. Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

6. Taipei Veterans General Hospital, Taiwan

7. Asistencia Cientifica de Alta Complejidad SAS, Bogota, Colombia

8. Desmond Tutu HIV Foundation, Cape Town, South Africa

9. Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey

Funder

Merck & Co., Inc.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/68/4/535/27699114/ciy540.pdf

Reference28 articles.

1. Beginning antiretroviral therapy for patients with HIV;Johnson;Infect Dis Clin North Am,2014

2. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations;Feng;Antimicrob Agents Chemother,2016

3. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor;Lai;Antimicrob Agents Chemother,2014

4. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways;Feng;Antimicrob Agents Chemother,2015

5. Sanchez RI , FillgroveK, HafeyM, et al In vitro evaluation of doravirine potential for pharmacokinetic drug interactions. Drug Metab Rev2016; 48(suppl 1):73.

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching to Doravirine in cART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost Savings;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-02-01

2. HIV epidemiology, prevention, treatment, and implementation strategies for public health;The Lancet;2024-02

3. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials;The Lancet HIV;2024-02

4. A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects;Recent Patents on Nanotechnology;2023-12

5. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV;Journal of Antimicrobial Chemotherapy;2023-11-24